IDH Inhibitors Target Common Glioma Mutation.

Mutant-selective IDH1 inhibitors engage their target in the brain and shrink glioma tumors with an acceptable safety profile, according to phase I trial data on three different drug candidates. However, some clinicians argue the drug strategy might be futile-or even make tumor progression worse. ©2019 American Association for Cancer Research.